FOSUN HEALTH Logo

Bone & Soft Tissue Tumors Treatment

catalogue

Bone & Soft Tissue Tumors Treatment

Bone & Soft Tissue Tumors Treatment

For almost every tumor in this family, the operation is the treatment that matters most, and everything else is arranged around it. A tumor removed whole with a margin of normal tissue around it gives the patient the best chance there is; the same tumor removed in pieces, or entered without a plan, is a much harder problem even when the later treatment is faultless. Chemotherapy, radiotherapy and targeted drugs are added according to the type of tumor, not according to its size, and each has a defined job around the operation rather than standing in for it.

The operation, and how it is planned

The operation for a bone or soft tissue sarcoma is called a wide excision: the tumor is removed as a single piece, together with a cuff of normal tissue around it. The cuff is not decorative. It exists because a sarcoma sends microscopic extensions into the tissue around it that cannot be seen on a scan or felt by hand, and removing the visible tumor alone would leave those behind. The operation is therefore an anatomical one — it is planned around the compartment or the tissue plane the tumor occupies, rather than around the lump.

Planning happens before the first incision, using the MRI and the CT. The surgeon decides which muscles must come out with the tumor, whether a segment of bone has to be removed, and where the incision should be placed so that it can incorporate the biopsy track. That last point explains an otherwise puzzling instruction: the biopsy entry point is often left visible and the scar is designed to include it, because a track that is not excised is a track that can seed.

The margin: the measurement that matters most

Once the tumor has been removed, the pathologist examines its surface and reports whether tumor cells are found at the cut edge. A margin that is negative means the tumor was surrounded by normal tissue; a margin that is positive means tumor cells are present at the edge of the specimen, and something must be done about it.

This finding is the strongest determinant of whether the tumor returns at the site it came from, and it explains why the word "close" appears so often in reports. A margin can be negative but narrow — measured in millimetres — and its meaning depends on the type of tumor: some sarcomas are infiltrative and return locally after a narrow excision, while others are well behaved. That is why the report specifies the distance and the type, rather than leaving the plan settled by the word "negative".

When the margin comes back positive or inadequately narrow, there are two options, and both are easier to plan for than to add later: a further operation to take more tissue from that area, or radiotherapy directed at the site. Occasionally the two are combined. This is also the reason a formal re-excision is planned immediately after an incomplete first operation rather than watched, and the reason the first operation is the one worth getting right.

Limb-sparing surgery, and what it really involves

Limb-sparing surgery means removing the tumor and the tissue it requires while leaving a limb that functions, rather than amputating. It is possible for the great majority of tumors of the arms and legs, and the honest version of the statement is that it is possible because the tumor is removed with a margin, not instead of that requirement. When the margin cannot be achieved any other way, sparing the limb would mean leaving disease behind, and the limb would be lost anyway — later, and after more treatment.

What it involves in practice is decided by what has to come out. A tumor in the thigh may require a group of muscles, and the limb will function differently afterwards: some movements are lost, others are taken over by neighbouring muscles through rehabilitation, and strength returns over months rather than weeks. A tumor in a bone may require a segment of that bone, which is then rebuilt. Nerve involvement complicates matters, because a nerve that cannot be preserved takes its function with it even when the limb is kept; a service that treats these tumors often has a nerve reconstruction or transfer available for exactly this situation.

The decision between sparing a limb and amputating is made with the patient rather than for them, and the conversation is about what they want to be able to do afterwards — walk unaided, return to a job, manage stairs, play with children. There is no single right answer, and a plan that does not match what the patient values is not a good plan even if the surgery is technically perfect.

Rebuilding the limb after the tumor is removed

Reconstruction is planned before the operation, not after it, and the method is chosen around the segment involved, the patient's age and what they need to return to. The options are well established, and each has a place.

  • A tumor prosthesis replaces the removed segment of bone and the joint next to it with an implant made for that purpose. It allows early weight-bearing and is often the choice for the hip and knee region in adults.
  • A bone graft uses donated bone to rebuild a segment, most often in younger patients where the bone may still be growing or where a large piece of the shaft has to be replaced.
  • A vascularised bone transfer takes a piece of the patient's own bone, usually the fibula, together with its blood supply, and joins it into the gap. It is used where the tissue has been irradiated or where the reconstruction must last a long time.
  • Soft tissue coverage brings a muscle or skin flap into the area to cover the reconstruction and to give it a blood supply. This is often the part that makes an ambitious reconstruction possible at all.
  • A rotationplasty turns the lower leg around and joins it to the thigh so that the ankle becomes the knee. It looks unfamiliar and functions well, and it grows with the patient.

Reconstruction is not the end of the treatment; it is the beginning of the rehabilitation. Implants wear, grafts take months to unite, and both need protection while they do, so the plan sets out what the patient may and may not do and for how long.

When amputation is the right operation

Amputation is performed when the tumor cannot be removed with a safe margin in any other way, and it removes the disease in the same single operation as a limb-sparing procedure. It is a treatment, not a failure, and framing it as a defeat does a disservice to patients who need it. The situations where it is the right choice are recognisable: a tumor that encases the major vessels and the nerve of the limb, one that has spread through several compartments, one that has recurred repeatedly in the same area after radiotherapy, and an infection in a reconstruction that cannot be cleared.

What the operation involves is planned in detail, because the level of the amputation determines how well a prosthesis can be fitted. Preserving as much length as possible is usually right, but not at the cost of a margin, and the level is decided with the prosthetics team rather than after the operation. Where the limb is amputated through a bone that has been irradiated, the wound needs the same attention to coverage and healing as any other reconstruction.

Rehabilitation after amputation is its own discipline: shaping the residual limb, fitting a prosthesis, learning to walk or to use the arm again, and managing the skin and the socket over years. It takes time and it works, and a service that treats these tumors should have the whole pathway available rather than the operation alone.

Chemotherapy: for the types that respond

Chemotherapy in this family of tumors is not given because the tumor is large or because the patient is anxious; it is given because the tumor type is known to respond. The types where systemic chemotherapy is part of standard treatment are the bone-forming sarcoma seen in adolescents and young adults, the small round cell tumor of bone and soft tissue, and a number of soft tissue sarcomas of particular subtypes. For other types — most cartilage-forming tumors, most fatty tumors of adults, and many spindle cell sarcomas — chemotherapy has no established role, and giving it would add side effects without adding benefit.

Where it is used, it is usually given before the operation as well as after it. There are two reasons. The first is that it treats microscopic disease that may already be present elsewhere, particularly in the lungs, at the earliest possible moment. The second is that the response of the tumor to the treatment can be measured: when the removed specimen is examined, the pathologist reports how much of the tumor has been killed, and that finding is used to decide what happens next. This is one of the few places in cancer treatment where the effect of a drug can be read directly from the tissue.

The schedule is given in cycles, with treatment days followed by an interval to allow the blood count to recover, and most of that time is spent at home rather than in hospital. The side effects are predictable and managed rather than endured: nausea is controlled with medication given before the treatment rather than after, the blood count is monitored and supported, and a fever during chemotherapy is a reason to attend immediately, not to wait for the morning.

Radiotherapy: mainly for soft tissue sarcoma

Radiotherapy is used in this family of tumors mostly for sarcomas of soft tissue, and for the small round cell tumor of bone and soft tissue where it is an active treatment in its own right. Its purpose around an operation is to sterilise the microscopic disease that lies beyond the margin, which is why it is offered when the margin is narrow or when the tumor type is known to return locally.

The timing is a real decision and is made with the type of tumor and the state of the wound in mind. Given before the operation, radiotherapy acts on tissue that has not been disturbed and is better oxygenated, and the field can be smaller because the tumor's position is known exactly; the trade-off is that the wound afterwards heals less reliably. Given after the operation, the wound is not irradiated and heals better, but the field is larger because the whole operative bed must be covered. Both approaches are established, and which is chosen depends on the site, the type and how the operation is expected to go.

It is given in small daily doses over several weeks, planned with imaging so that the dose reaches the tissue that needs it. Skin reactions, tiredness and stiffness in the treated area are the commonest effects and are managed as the course proceeds. Radiotherapy does not remove the need for a good operation: it extends the operation's reach, and it cannot compensate for a tumor that was left behind.

Targeted drugs, and the tumors with a drug of their own

A small number of tumors in this family are defined by a change that a drug can act on directly, and for those the drug is not an add-on but the backbone of treatment. The clearest example is the tumor of the gut wall driven by a change in one of two related genes: a drug aimed at that pathway controls it where conventional chemotherapy does not, given before an operation to shrink the tumor and after one to keep it controlled. Drugs aimed at rare fusions are now available for the tumors that carry them, wherever they started.

What makes this different from chemotherapy is selectivity. A targeted drug acts on a specific change in the tumor cells, which is why the molecular test matters so much, and why two tumors that look identical under the microscope may be treated completely differently. It also explains the pattern of side effects: they follow from the pathway being blocked rather than from general damage to dividing cells.

The honest qualification is that targeted treatment is not available for most sarcomas, and the number of types with a matched drug is small. Where it does apply, it applies decisively — and identifying those cases is one of the reasons molecular testing is done on the biopsy rather than only after the operation.

If the bone has already broken

A fracture through a bone that has been weakened by a tumor changes the plan, and understanding why is worth a paragraph. The bone is unstable, the tumor has been exposed to the surrounding tissue in a way it had not been before, and the limb may be painful and unusable. The fracture is therefore dealt with in the same plan as the tumor rather than as a separate emergency attended to and then forgotten.

If the fracture is in a limb where the tumor can be removed and the segment rebuilt, the operation addresses both problems at once: the tumor comes out with its margin and the bone is reconstructed, often with a prosthesis. If the tumor is one that responds to chemotherapy, the fracture does not necessarily change that, though the timing of the operation may be brought forward. Where the fracture is in a bone that is not itself the site of the tumor, or where the disease is widespread, the fracture may be stabilised first and the tumor treated according to its own plan.

What the patient needs to know is practical: do not walk on a limb that has broken or that gives way, attend the same day for assessment and imaging, and expect the plan to be reassessed. A bone stabilised before it breaks remains a much easier problem than one that has already broken.

Rehabilitation: the part that decides how well life works

Rehabilitation is not an afterthought in this disease; it is the part of the treatment that determines what a patient can do once the tumor is gone. It starts before the operation, with an assessment of the strength and movement that exist and what the patient needs back, and it continues for months afterwards. Planning for it in advance is what allows early, safe movement rather than prolonged rest.

  • Early movement and weight-bearing, within the limits the reconstruction allows. The limits are specific — a prosthesis, a graft and a vascularised transfer each tolerate different loads — and they are set by the surgical team.
  • Strength and range of movement, rebuilding what the operation removed and teaching neighbouring muscles to take over. Progress is measured in weeks and months rather than days.
  • Walking and function, with a prosthesis after amputation and with gait retraining after a limb-sparing procedure. Both take a defined course and both work better with a named therapist than with general advice.
  • Swelling and wound care in the early weeks, which affects the whole recovery: a limb that is swollen moves less, and movement is what prevents stiffness.

The realistic expectation is that recovery is measured in months and that some things will not come back exactly as they were. What is achievable is usually more than patients expect at the outset, and it depends heavily on doing the rehabilitation consistently rather than on the technique used.

Follow-up: what is watched, and why

Follow-up after treatment for a bone or soft tissue tumor is designed around two questions: has the tumor returned where it was, and has it appeared in the lungs. Those two sites account for the great majority of what surveillance is looking for, and they are the reason the schedule is built around imaging of the operative site and of the chest rather than around blood tests.

The schedule is denser in the first few years and then widens, because that is when recurrence is most likely for most tumor types. Imaging of the original site is usually an MRI where the tumor was in soft tissue or a complex site, and the chest is imaged with CT. The intervals are set for the tumor type and the grade rather than fixed for everyone, and if a patient moves or travels, the schedule is arranged in writing before they leave so that it can be carried out locally and the images sent for review.

Surveillance works best when the images are read by someone who knows what the original tumor looked like, which is why sending images rather than only reports matters. And patients notice things a scan does not — a new lump, a pain that does not settle, a change in how the limb works — which belong in the appointment rather than saved for the next scan.

Frequently Asked Questions

Is the operation always the first treatment?

For most tumors in this family, no, and this is one of the least intuitive things about the treatment. Where the tumor type responds to chemotherapy, the treatment is deliberately given before the operation: it acts on microscopic disease elsewhere at the earliest opportunity, and it allows the effect of the drug to be measured on the specimen that is eventually removed. Where the tumor type responds to radiotherapy and the margin is expected to be narrow, radiotherapy may also be given first. For the types that respond to neither — which includes most cartilage-forming and many fatty tumors of adults — the operation comes first, and that is not a delay in treatment but the correct order.

What does it mean if the margin is not clear?

It means tumor cells were found at the edge of the removed piece, and it is a finding that is acted on rather than noted. The two routes are a further operation to remove more tissue from that area — which is usually possible while the operative field is still planned and known — or radiotherapy directed at the site to sterilise what remains. Which is chosen depends on the type of tumor, where it is, and whether radiotherapy was already given or is planned. A positive margin is not the same as a failed operation, but it does change what happens next, and it is the reason the pathology report is read carefully rather than skimmed for the tumor name.

Will I be able to walk normally after limb-sparing surgery?

Most patients walk without aids, and the honest answer is that the gait is usually not identical to what it was before. What determines the outcome is which structures had to be removed, how the limb was rebuilt, and how consistently the rehabilitation is done. A tumor in the thigh that requires a group of muscles leaves a limb that is strong but has lost some specific movements; a reconstruction around the knee affects how the knee bends and how walking feels on slopes. These effects are real and they are manageable, and the realistic picture is usually clearer when the surgeon, the physiotherapist and the patient plan the rehabilitation together before the operation rather than after it.

Do I have to stay in hospital for the whole treatment?

No, and the rhythm of the treatment is worth knowing in advance because it shapes the practical arrangements. Chemotherapy is given in cycles, with treatment days followed by an interval, and most of that time is spent at home; radiotherapy is given in short daily sessions over several weeks, which can be arranged around accommodation. The operation is the part that requires a hospital stay and a period of protected recovery afterwards, and its length depends on what was removed and how it was rebuilt. Many patients coming from abroad plan the stay around the operation and the beginning of rehabilitation, and return home to continue the rest of the follow-up under a local arrangement.

Send the images and the pathology, get a treatment view

Upload the MRI, the radiograph and the chest imaging as images with their reports and dates, the biopsy and pathology report in full, any molecular testing already carried out, and the operative notes if an operation has taken place. Our sarcoma team will return a written opinion within about 48 hours of the file being complete, setting out how the tumor would be treated, whether the operation should be planned with or without treatment before it, and what the reconstruction would involve.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

WhatsApp +86 172-7459-8280 · EN / 中文 · 24h within business hours

Follow Fosun Health

Apply for an Appointment

Do you have test results*